Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rectal Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Rectal Cancer - Pipeline Review, H1 2016', provides an overview of the Rectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Rectal Cancer therapeutics and enlists all their major and minor projects - The report assesses Rectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Rectal Cancer Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Rectal Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Rectal Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Rectal Cancer - Overview 7 Rectal Cancer - Therapeutics under Development by Companies 8 Rectal Cancer - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Rectal Cancer - Products under Development by Companies 11 Rectal Cancer - Companies Involved in Therapeutics Development 12 AbbVie Inc. 12 Advaxis, Inc. 13 Cerulean Pharma, Inc. 14 Hanwha Chemical Corporation 15 Karyopharm Therapeutics, Inc. 16 Regeneron Pharmaceuticals, Inc. 17 Synta Pharmaceuticals Corp. 18 Taiwan Liposome Company, Ltd. 19 Rectal Cancer - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 axalimogene filolisbac - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 CB-24 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 CRLX-101 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ganetespib - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 HD-204 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 nimotuzumab - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 selinexor - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 TLC-388 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 veliparib - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ziv-aflibercept (recombinant) - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Rectal Cancer - Recent Pipeline Updates 64 Rectal Cancer - Dormant Projects 108 Rectal Cancer - Product Development Milestones 109 Featured News & Press Releases 109 Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting 109 Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 109 Appendix 111 Methodology 111 Coverage 111 Secondary Research 111 Primary Research 111 Expert Panel Validation 111 Contact Us 111 Disclaimer 112
List of Tables Number of Products under Development for Rectal Cancer, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Rectal Cancer - Pipeline by AbbVie Inc., H1 2016 12 Rectal Cancer - Pipeline by Advaxis, Inc., H1 2016 13 Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 14 Rectal Cancer - Pipeline by Hanwha Chemical Corporation, H1 2016 15 Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 16 Rectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 17 Rectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 18 Rectal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Rectal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 64 Rectal Cancer - Dormant Projects, H1 2016 108
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.